IO Frontiers World 2019


Pawel Kalinski

Dr Pawel Kalinski

Vice Chair for Translational Research and Professor of Oncology, Department of Medicine,Director of Cancer Vaccine and Dendritic Cell Therapies, Center for Immunotherapy, Co-Leader, Tumor Immunology & Immunotherapy Program, Roswell Park Cancer Institute

Pawel Kalinski, MD, PhD, is the Vice-Chair for Translational Research in the Department of Medicine, Director of Cancer Vaccine and Dendritic Cell Therapies in the Center for Immunotherapy, and a Co-Leader of the Tumor Immunology & Immunotherapy Program of the Roswell Park Cancer Institute in Buffalo, NY. He obtained MD in 1990 from the Medical University of Warsaw, Poland, and PhD (Immunology) in 1989 from the University of Amsterdam, the Netherlands. 

The research of Dr. Kalinski addresses: 1) Modulation of tumor microenvironments (TME) to enhance local CTL accumulation and sensitize tumors to checkpoint blockade; 2) Counteracting secondary suppressive mechanisms to enhance the effectiveness of cancer immunotherapies; 3) Development of cellular therapeutics against cancer (DC vaccines and DC-sensitized T cells); 4) Crosstalk-between chemo- radio- and immunotherapy.

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy